INTRODUCTION
Atopic dermatitis and prurigo nodularis represent the two most burdensome pruritic inflammatory skin diseases encountered in clinical dermatology. While distinct in morphology, chronicity, and epidemiology, both conditions are united by a common pathophysiologic axis: type 2 immune dysregulation, peripheral neuronal sensitization, collagen deposition resulting in lichenification or nodule formation, and the relentless itch-scratch cycle that profoundly impairs quality of life. At the molecular center of this axis sits interleukin-31, a cytokine that has earned the designation "the itchy cytokine" for its potent, direct pruritogenic activity.1
Over the past decade, the biology of IL-31 has been systematically characterized across its receptor signaling machinery, cellular sources, downstream immunologic and neuronal effects, and epidermal consequences. Simultaneously, the therapeutic potential of interrupting IL-31 signaling has been validated through an extensive clinical development program for nemolizumab, a subcutaneously administered humanized monoclonal antibody targeting IL-31RA. The convergence of this mechanistic understanding with robust clinical evidence across two indications provides a unique opportunity to synthesize what is known about IL-31 and to contextualize the therapeutic implications of targeting its receptor.
This manuscript provides an integrated review of IL-31 pathophysiology in AD and PN and the clinical efficacy of nemolizumab across both indications, with attention to skin clearance, pruritus control, sleep restoration, long-term durability, and translational biomarker insights. A discussion section contextualizes these findings within the broader biologics landscape, addresses the mechanistic significance of key clinical observations, and outlines priority areas for future investigation.
Contextualizing Interleukin-31 in Atopic Dermatitis
Epidemiological Context and the Role of Type 2 Inflammation
Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, barrier dysfunction, and dysregulated immune activation. It affects up to 20% of children and approximately 10% of adults worldwide, imposing substantial burdens on quality of life and healthcare systems.2 The pathogenesis of AD is multifactorial, involving genetic
Over the past decade, the biology of IL-31 has been systematically characterized across its receptor signaling machinery, cellular sources, downstream immunologic and neuronal effects, and epidermal consequences. Simultaneously, the therapeutic potential of interrupting IL-31 signaling has been validated through an extensive clinical development program for nemolizumab, a subcutaneously administered humanized monoclonal antibody targeting IL-31RA. The convergence of this mechanistic understanding with robust clinical evidence across two indications provides a unique opportunity to synthesize what is known about IL-31 and to contextualize the therapeutic implications of targeting its receptor.
This manuscript provides an integrated review of IL-31 pathophysiology in AD and PN and the clinical efficacy of nemolizumab across both indications, with attention to skin clearance, pruritus control, sleep restoration, long-term durability, and translational biomarker insights. A discussion section contextualizes these findings within the broader biologics landscape, addresses the mechanistic significance of key clinical observations, and outlines priority areas for future investigation.
Contextualizing Interleukin-31 in Atopic Dermatitis
Epidemiological Context and the Role of Type 2 Inflammation
Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, barrier dysfunction, and dysregulated immune activation. It affects up to 20% of children and approximately 10% of adults worldwide, imposing substantial burdens on quality of life and healthcare systems.2 The pathogenesis of AD is multifactorial, involving genetic
